Mid-market growth fund research profile
CX Partners is an Indian mid-market private-equity group focused on healthcare, financial services, consumer products and IT-enabled services. It positions itself as an involved partner, combining disciplined origination with active portfolio support and planned exit routes.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
CX Partners uses a mid-market growth approach across Fin services, health, consumer.
Current evidence
CX Partners’ current website reports $630 million of funds under advisory, 29 portfolio companies and two registered Category II AIFs, including CX Alternative Investment Fund 3. Current attributable evidence includes Thyrocare Technologies and Healthium Medtech, which Apax identifies as a former CX Partners investment; Fund 3’s August 2024 close is reported by Private Equity International.
Strategy
Mid-market growth
Sector focus
Fin services, health, consumer
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
CX Partners’ current website reports $630 million of funds under advisory, 29 portfolio companies and two registered Category II AIFs, including CX Alternative Investment Fund 3. Current attributable evidence includes Thyrocare Technologies and Healthium Medtech, which Apax identifies as a former CX Partners investment; Fund 3’s August 2024 close is reported by Private Equity International.
Investor questions
CX Partners is covered in Rupeia's private equity research universe. The current public record describes the strategy as Mid-market growth, with a sector focus of Fin services, health, consumer. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to CX Partners in the reviewed public sources: Thyrocare Technologies, Healthium Medtech, Dindigul Thalappakatti Hotels, Indifi Technologies. It does not represent a complete current portfolio unless the manager has published one.
CX’s website describes a long track record of returns through cycles and multiple exit options, while independent reporting records exits including Biryani By Kilo and the sale of Healthium Medtech. The reviewed public record does not disclose consolidated fund IRR or DPI. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: CX publicly identifies Category II CX Alternative Investment Fund and CX Alternative Investment Fund 3; current vehicle sizes are not disclosed on the manager’s website.. Public terms or access information: Mid-market growth and buyout-style investing across healthcare, financial services, consumer and IT services; cheque and reserve ranges are not consistently disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Vivek Chhachhi (Managing Partner), Manu Sahni (Managing Director), Mansi Goel (Senior Director, Investor Relations). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: The current manager site does not expose a complete named portfolio schedule, so only attributable names supported by company or transaction evidence are retained; fund-level returns remain not publicly disclosed..
2024-08-31: CX Partners’ current website reports $630 million of funds under advisory, 29 portfolio companies and two registered Category II AIFs, including CX Alternative Investment Fund 3. Current attributable evidence includes Thyrocare Technologies and Healthium Medtech, which Apax identifies as a former CX Partners investment; Fund 3’s August 2024 close is reported by Private Equity International.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.